Should I Buy CORT? CORT 2026 Analysis

Should You Buy Corcept Therapeutics Inc (CORT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

45.850

1 Day change

-0.80%

52 Week Range

117.330

Analysis Updated At

2026/01/28

Buy now for a long-term position. The technical setup has turned bullish after the recent catalyst-driven rebound, and the latest Phase 3 ROSELLA overall-survival update meaningfully improves the probability of value creation into the July 11, 2026 FDA action date for ovarian cancer. While the prior FDA complete response letter created an overhang for the Cushing’s indication, current analyst revisions and price targets skew positive again, suggesting Wall Street is refocusing on the oncology opportunity and a still-strong core Korlym business.

Technical Analysis

Price is $46.16, holding above the pivot/support area (Pivot ~40.34) and above R1 (~45.40), which is a constructive breakout/hold level. Next resistance is R2 (~48.53); a push through that level would confirm continuation. Momentum is bullish: MACD histogram is positive and expanding (2.459), indicating strengthening upside momentum. RSI(6) is ~68.98, near the upper end of neutral and close to overbought—this suggests upside momentum is strong but the stock may also be prone to short pullbacks while still trending up. Moving averages are converging, consistent with a trend transition rather than an exhausted move. Near-term pattern stats suggest modest drift over a week and stronger odds over a month (+4.45% expected tendency), aligning with a bullish intermediate setup.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options positioning shows mixed-to-bullish near-term sentiment: open interest put/call of 1.19 implies heavier put positioning (often hedging or cautious positioning after major volatility), while today’s put/call volume of 0.03 indicates call volume dominated trading activity (bullish/positive reaction flow). Implied volatility is elevated (30D IV ~70.45 vs HV ~68.58), consistent with event-driven pricing (FDA/clinical updates).

Technical Summary

Sell

Buy

Positive Catalysts

["Phase 3 ROSELLA trial update: relacorilant reduced ovarian cancer death risk by ~35% and showed durable OS benefit; this is a major sentiment and valuation catalyst.", "Upcoming FDA action date (noted by analysts) for ovarian cancer on July 11, 2026\u2014clear event-driven runway.", "Analysts (Canaccord, H.C. Wainwright) raised price targets materially post-data, indicating improving Street confidence.", "Core Korlym business described by analysts as still strong, supporting ongoing revenue base."]

Neutral/Negative Catalysts

["Recent FDA complete response letter (CRL) for relacorilant in hypercortisolism/Cushing\u2019s-related indication: potential requirement for additional confirmatory evidence/trial delays near-term expansion plans.", "High volatility regime (options IV ~70%) implies sharp moves can occur around headlines and upcoming earnings.", "Next earnings (QDEC 2025) on 2026-02-19 after hours could be another swing catalyst."]

Financial Performance

Latest reported quarter: 2025/Q3. Revenue grew to $207.64M (+13.75% YoY), showing continued top-line expansion. Profitability weakened: net income fell to $19.67M (-58.34% YoY) and EPS to $0.16 (-61.90% YoY), indicating margin/expense pressure despite strong gross margin (97.79%, slightly down YoY). Overall: growth remains solid, but earnings momentum in the latest quarter was negative.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: sharply mixed after the FDA CRL (late Dec/early Jan) with a notable bear turn from Wolfe Research (downgrade to Underperform, $30 PT) and large PT cuts from bulls (e.g., Truist to $50; Canaccord to $99; H.C. Wainwright to $90). However, following the strong ROSELLA survival update (Jan 22–23), bullish analysts re-raised targets (Canaccord to $100; H.C. Wainwright to $105) and reiterated Buy ratings, reflecting renewed confidence driven by the ovarian cancer pathway. Wall Street pros: durable OS data, large oncology upside, and a strong base business. Cons: regulatory setback/uncertainty in Cushing’s pathway and the possibility of additional trials delaying that leg of growth. Influential/political trading: no recent Congress trading data available; hedge funds and insiders show neutral recent activity.

6 Analyst Rating

Wall Street analysts forecast CORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CORT is 91 USD with a low forecast of 50 USD and a high forecast of 121 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

1 Sell

Moderate Buy

Current: 46.220

Low

Averages

High

121

Current: 46.220

Low

Averages

High

121

Canaccord

Buy

maintain

$99 -> $100

AI Analysis

2026-01-23

Reason

Canaccord

Price Target

$99 -> $100

AI Analysis

2026-01-23

maintain

Buy

Reason

Canaccord raised the firm's price target on Corcept Therapeutics to $100 from $99 and keeps a Buy rating on the shares. The firm noted they reported final overall survival (OS) data from the company's Phase III ROSELLA trial in patients with platinum-resistant ovarian cancer (PROC). The data showed durability as the previously reported interim median OS improvement of 4.5 months was maintained and 2025 revenue estimates were increased with in guidance.

H.C. Wainwright

Swayampakula Ramakanth

Buy

maintain

$90 -> $105

2026-01-22

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

$90 -> $105

2026-01-22

maintain

Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Corcept Therapeutics to $105 from $90 and keeps a Buy rating on the shares. Citing "strong" survival data, the firm increased its market penetration to 25% from 20% for relacorilant in ovarian cancer. Corcept announced positive median overall survival data from its pivotal Phase 3 ROSELLA study in platinum-resistant ovarian cancer, the analyst tells investors in a research note. H.C. Wainwright believes the data bodes well for the upcoming FDA action date on July 11.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CORT

Unlock Now

CORT Should I Buy

CORT Should I Buy

Should You Buy Corcept Therapeutics Inc (CORT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch